Eli Lilly reports Q1 EPS $8.55, consensus $6.79

Reports Q1 revenue $19.8B, consensus $17.8B. Q1 non-GAAP EPS included 52c of acquired IPR&D charges compared to $1.72 in Q1 2025. “2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion,” said David A. Ricks, Lilly chair and CEO. “A key milestone was the U.S. FDA approval of Foundayo-the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions. Foundayo will meaningfully expand the number of people who can benefit from GLP-1s. We also delivered pipeline progress across all four therapeutic areas and continued investing in Lilly’s future growth through four acquisitions.”